Zosano Pharma is a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using its proprietary intracutaneous microneedle system (the System). Co.'s development activities are focused on its product candidate, Qtrypta (M207). Qtrypta (M207) is Co.'s proprietary formulation of zolmitriptan delivered utilizing its System. Zolmitriptan is one of a class of serotonin receptor agonists known as triptans and is used as an acute treatment for migraine. Qtrypta (M207) is designed for absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal tract. The ZSAN stock yearly return is shown above.
The yearly return on the ZSAN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ZSAN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|